Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ENO1 | P06733 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL11682036 | 0.98 | MEN1 (0.39) | MEN1LMNAHPGDTSHRBLM | |
| Ammonia Solution, Strong SCHEMBL11682038 | 0.98 | MEN1 (0.39) | MEN1LMNAHPGDTSHRBLM | |
| Butane SCHEMBL97927 | 0.94 | MEN1 (0.36) | MEN1LMNAHPGDTSHRBLM | |
| Diethylamine SCHEMBL27878057 | 0.88 | ENO1 (0.33) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL799524 | 0.81 | DGAT1 (0.33) | TDP1DGAT1CYP2D6HDAC3HDAC1 | |
| SCHEMBL1692278 | 0.80 | MEN1 (0.36) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL1327919 | 0.80 | MEN1 (0.36) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL7514893 | 0.79 | LMNA (0.34) | MEN1LMNAHPGDTSHRBLM | |
| SCHEMBL28160941 | 0.77 | L3MBTL1 (0.33) | DGAT1CYP2D6HDAC3HDAC1HDAC2 | |
| SCHEMBL421908 | 0.77 | DGAT1 (0.35) | LMNADGAT1CYP2D6HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447355-A | Preparation method of milbelin intermediate | 南京威凯尔生物医药科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-114195661-B | Preparation method of milobalin benzenesulfonate | 苏州楚凯药业有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-112384493-B | Process for preparing fused tricyclic gamma-amino acid derivatives and intermediates | 四川海思科制药有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115557964-A | Preparation method of pharmaceutical compound | 启东东岳药业有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-113480545-B | Imidazopyrazinone compound and preparation method and application thereof | 山东大学 | 2022-08-26 | — | — | CN | claimed |
| CN-114195661-A | Preparation method of milobalin besylate | 苏州楚凯药业有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-113480545-A | Imidazopyrazinone compound and preparation method and application thereof | 山东大学 | 2021-10-08 | — | — | CN | claimed |
| CN-112384493-A | Process for the preparation of fused tricyclic gamma-amino acid derivatives and intermediates | 四川海思科制药有限公司 | 2021-02-19 | — | — | CN | claimed |
| WO-2020029762-A1 | PREPARATION METHOD FOR FUSED TRICYCLIC γ-AMINO ACID DERIVATIVE AND INTERMEDIATE THEREOF | 四川海思科制药有限公司 | 2020-02-13 | — | — | WO | claimed |
| CN-117945887-A | Preparation method of milbelin intermediate (2E) -4-ethylheptyl-2, 6-dienoic acid | 山东新时代药业有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-114214375-B | Process for the preparation of (R) -3- (4-halo-1H-pyrazol-1-yl) -3-cyclopentylpropionate | 江苏威凯尔医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-114195661-B | Preparation method of milobalin benzenesulfonate | 苏州楚凯药业有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114195661-B | Preparation method of milobalin benzenesulfonate | 苏州楚凯药业有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116462576-B | Preparation method of key intermediate of milabalin | 山东新时代药业有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-6846802-B2 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030125389-A1 | Beta-amino acid derivatives useful for the treatment of bacterial infections | VERSICOR, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | SCHERING CORPORATION | 2002-08-08 | — | — | US | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
| US-4052439-A | TREATMENT OF HERPES SIMPLEX INFECTIONS | ABBOTT LABORATORIES (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125389-A1 | Beta-amino acid derivatives useful for the treatment of bacterial infections | BCAT2, BCAT1, AADAT | MEN1 1491/4885LMNA 2729/4885HPGD 977/4885 |
| US-20020107181-A1 | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties | HPN, TMPRSS15, HAVCR2 | MEN1 4279/4885LMNA 2923/4885HPGD 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.